These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 18000219)

  • 1. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
    J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't.
    Jordan VC
    J Natl Cancer Inst; 2007 Nov; 99(22):1655-7. PubMed ID: 18000213
    [No Abstract]   [Full Text] [Related]  

  • 3. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription.
    Harte MT; O'Brien GJ; Ryan NM; Gorski JJ; Savage KI; Crawford NT; Mullan PB; Harkin DP
    Cancer Res; 2010 Mar; 70(6):2538-47. PubMed ID: 20215511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
    Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
    Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
    Zhang L; Cui J; Leonard M; Nephew K; Li Y; Zhang X
    PLoS One; 2013; 8(7):e70641. PubMed ID: 23936234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
    Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
    Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines.
    Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R
    Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
    Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
    Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
    Lewis JS; Meeke K; Osipo C; Ross EA; Kidawi N; Li T; Bell E; Chandel NS; Jordan VC
    J Natl Cancer Inst; 2005 Dec; 97(23):1746-59. PubMed ID: 16333030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
    Patani N; Dunbier AK; Anderson H; Ghazoui Z; Ribas R; Anderson E; Gao Q; A'hern R; Mackay A; Lindemann J; Wellings R; Walker J; Kuter I; Martin LA; Dowsett M
    Clin Cancer Res; 2014 Aug; 20(15):3962-73. PubMed ID: 24916694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
    Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.
    Moy I; Todorović V; Dubash AD; Coon JS; Parker JB; Buranapramest M; Huang CC; Zhao H; Green KJ; Bulun SE
    Oncogene; 2015 Jan; 34(3):323-33. PubMed ID: 24413080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia reduces hormone responsiveness of human breast cancer cells.
    Kurebayashi J; Otsuki T; Moriya T; Sonoo H
    Jpn J Cancer Res; 2001 Oct; 92(10):1093-101. PubMed ID: 11676860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Wen J; Li R; Lu Y; Shupnik MA
    Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.